SEC Form 4 · accession 0000902664-26-003254
Scribe Therapeutics, Inc. · SCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Avoro Capital Advisors LLC
Director · Other
Behzad Aghazadeh
Director · Other
Avoro Ventures LLC
Director · Other
Period of report
Jul 23, 2026
Accepted (ET)
Jul 27, 2026 · 9:04 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001853921
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3,F1 | $15.00 | Jul 23, 2026 | A | 14,725 | A | — | Jul 22, 2036 | Common Stock | 14,725 | 14,725 | D |
Explanation of responses
- F1The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date.
- F2This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
- F3The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.
Remarks
Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.